PDS Biotechnology Corporation
NASDAQ:PDSB
1.56 (USD) • At close June 5, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.06 | 0.057 | 0.049 | 0.246 | 0.176 | 0.098 | 0.069 | 0.183 | 0.1 | 0.053 | 0 | 0 | 0.002 |
| Gross Profit
| -0.06 | -0.057 | -0.049 | -0.246 | -0.176 | -0.098 | -0.069 | -0.183 | -0.1 | -0.053 | 0 | 0 | -0.002 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 22.566 | 27.762 | 29.431 | 11.255 | 7.924 | 6.1 | 0.831 | 34.312 | 24.825 | 17.84 | 8.474 | 4.484 | 3.705 |
| General & Administrative Expenses
| 0 | 15.018 | 12.241 | 10.185 | 6.962 | 10.982 | 14.291 | 17.655 | 14.687 | 8.659 | 4.721 | 2.004 | 0 |
| Selling & Marketing Expenses
| 0 | 0.264 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 13.696 | 15.282 | 12.241 | 10.185 | 6.962 | 10.982 | 14.291 | 17.655 | 14.687 | 8.659 | 4.721 | 2.004 | 0.981 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0.016 | 3,953.273 | 12,736.79 | 0 | -0.163 | -1.88 | 0 | 0 | 0 |
| Operating Expenses
| 36.261 | 43.045 | 41.672 | 21.439 | 14.726 | 15.411 | 3.646 | 51.967 | 39.512 | 26.499 | 13.194 | 6.488 | 4.686 |
| Operating Income
| -36.321 | -43.045 | -41.672 | -21.439 | -14.902 | -21.035 | -43.097 | -51.967 | -39.512 | -26.499 | -13.194 | -6.488 | -4.688 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -2.158 | -1.303 | -0.381 | 0.004 | 0 | 13.654 | 0 | 0 | -0.26 | -2.687 | 0.402 | -0.854 | -0.01 |
| Income Before Tax
| -38.48 | -44.348 | -42.054 | -21.435 | -14.847 | -7.38 | -3.836 | -53.446 | -40.667 | -29.186 | -12.792 | -7.342 | -4.698 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0.869 | -1.406 | -1.199 | -4.516 | -0.136 | -0.382 | -2.782 | -2.586 | 0 | -1.107 | -0.591 | -0.459 | 0 |
| Net Income
| -37.61 | -42.942 | -40.855 | -16.918 | -14.847 | -6.999 | -40.868 | -50.86 | -38.821 | -28.079 | -12.201 | -6.883 | -4.698 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1,079.45 | -1.39 | -1.43 | -0.66 | -0.89 | -1.44 | -26.16 | -33.47 | -26.9 | -69.43 | -16.15 | -9.11 | -3.3 |
| EPS Diluted
| -1,079.45 | -1.39 | -1.43 | -0.66 | -0.89 | -1.44 | -26.16 | -33.47 | -26.9 | -69.43 | -16.15 | -9.11 | -3.3 |
| EBITDA
| -33.747 | -40.085 | -40.688 | -21.189 | -14.671 | -16.983 | -3.577 | -51.083 | -39.363 | -28.316 | -12.578 | -7.334 | -4.693 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |